← Back to Search

Antiepileptic

Wait control for Stroke

Phase 1
Waitlist Available
Led By A.M. Barrett, MD
Research Sponsored by Kessler Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months - 1year
Awards & highlights

Study Summary

This trial looks at whether the drug levetiracetam can help improve symptoms in people who have chronic aphasia due to a stroke.

Eligible Conditions
  • Stroke
  • Aphasia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months - 1year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months - 1year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Speech and language assessment
Secondary outcome measures
Memory assessment

Trial Design

2Treatment groups
Experimental Treatment
Group I: Wait controlExperimental Treatment1 Intervention
Levitiracetam is started after a delay, with dosage and administration as described below.
Group II: Treatment firstExperimental Treatment1 Intervention
Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.

Find a Location

Who is running the clinical trial?

Kessler FoundationLead Sponsor
174 Previous Clinical Trials
10,688 Total Patients Enrolled
26 Trials studying Stroke
2,423 Patients Enrolled for Stroke
UCB PharmaIndustry Sponsor
341 Previous Clinical Trials
109,269 Total Patients Enrolled
A.M. Barrett, MDPrincipal InvestigatorKessler Foundation
1 Previous Clinical Trials
12 Total Patients Enrolled
1 Trials studying Stroke
12 Patients Enrolled for Stroke

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
A. M. Barrett, MD 2005. "Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00227461.
All > Aphasia
~3 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top